Retrophin Inc. (NASDAQ:RTRX) shares were down 4.9% during trading on Monday . The company traded as low as $17.49 and last traded at $17.57, with a volume of 291,310 shares changing hands. The stock had previously closed at $18.48.

Several analysts have issued reports on RTRX shares. Zacks Investment Research downgraded shares of Retrophin from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 6th. Leerink Swann reissued a “buy” rating on shares of Retrophin in a research note on Wednesday, May 11th. BMO Capital Markets reissued a “buy” rating on shares of Retrophin in a research note on Wednesday, May 4th. Finally, JMP Securities reissued a “buy” rating on shares of Retrophin in a research note on Saturday, July 9th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Retrophin presently has an average rating of “Buy” and a consensus price target of $23.60.

The company has a 50-day moving average price of $17.91 and a 200 day moving average price of $15.97. The company has a market cap of $645.50 million and a price-to-earnings ratio of 9.16.

Retrophin (NASDAQ:RTRX) last released its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.36. The firm earned $29 million during the quarter, compared to analysts’ expectations of $31 million. The business’s quarterly revenue was up 66.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.18) earnings per share. On average, equities research analysts anticipate that Retrophin Inc. will post $0.08 EPS for the current year.

In other news, EVP Alvin Shih sold 8,750 shares of Retrophin stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $17.75, for a total value of $155,312.50. Following the completion of the transaction, the executive vice president now directly owns 167,084 shares in the company, valued at $2,965,741. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Other institutional investors recently made changes to their positions in the company. Turner Investments L.P. boosted its position in shares of Retrophin by 61.6% in the fourth quarter. Turner Investments L.P. now owns 384,760 shares of the biopharmaceutical company’s stock valued at $7,422,000 after buying an additional 146,720 shares during the period. Cornerstone Capital Management Holdings LLC. raised its stake in Retrophin by 1,449.5% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 91,421 shares of the biopharmaceutical company’s stock valued at $1,763,000 after buying an additional 85,521 shares in the last quarter. Tekla Capital Management LLC acquired a new stake in Retrophin during the fourth quarter valued at about $6,365,000. Finally, California State Teachers Retirement System raised its stake in Retrophin by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 64,781 shares of the biopharmaceutical company’s stock valued at $1,250,000 after buying an additional 1,129 shares in the last quarter.

Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.